Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

enforcement

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

Policy and public health: all the decisions we can’t see

January was a bad month for healthcare in China

- PMLiVE

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance

- PMLiVE

Transparency and accountability: tackling opacity and blame head-on

Let’s be honest, big pharma lacks trust and many love to hate it. Faceless corporations tainted by past own-goals, profiteering, cherry-picked data and spun claims - so goes the lazy...

- PMLiVE

FDA ‘names and shames’ generic-blocking pharma companies

Celgene and Actelion top the list of offenders

- PMLiVE

Is trust in healthcare improving?

Edelman’s Annual Trust Barometer for 2017 painted a sobering picture of trust around the globe with a collapse in trust in all four of the major institutions studied - business,...

ABPI London offices

Nearly half of HCPs refuse to disclose pharma payments

Industry data shows firms spent £363m on working with healthcare professionals

- PMLiVE

Tracking comms trends: tackling reputational issues head on

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

- PMLiVE

Leveraging HCP transparency insights to drive future customer investments

EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness

Celgene building

Celgene: Patient voice often underrepresented in pricing debates

Dr Jackie Fouse says in the interests of transparency patients should be more involved

- PMLiVE

The big picture

Cost talks should go hand-in-hand with value discussions

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links